The presence of EGFR gene amplification in a substantial portion of SCCHN and the previously reported associations between EGFR gene amplification and response to EGFR-targeted therapies in other cancers suggest that EGFR gene amplification may be a predictive marker for response to EGFR-targeted therapies in SCCHN. Here, EGFR is linked to head and neck squamous cell carcinoma.